Clinical Trials in Colorado

Showing 10861-10880 of 15,592 trials

Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy

NCT03089476

It is hypothesized that food allergy is preceded by atopic dermatitis (AD), due to a disruption of skin barrier which can predispose one to food sensitization through the skin. The central hypothesis is that increased transepidermal water loss (TEWL) assessment and skin tape strip analysis (STS) of lipid and filaggrin breakdown products will be predictive markers for the development of AD. Additionally, the associated changes in TEWL and STS will further improve the identification of infants at risk of early food sensitization, compared to family history alone.

Atopic DermatitisEczemaFood Allergy

National Jewish HealthStarted Sep 2017

Denver, Colorado, United States

COMPLETEDPhase 350 miles

A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation

NCT02392234

The purpose of this study is to evaluate the efficacy and safety of VX-661 in combination with ivacaftor (IVA, VX-770) and IVA monotherapy in participants with Cystic Fibrosis (CF) who are heterozygous for F508del-CFTR allele and a second allele with a CFTR mutation predicted to have residual function.

Cystic Fibrosis

Vertex Pharmaceuticals Incorporated248 participantsStarted Mar 2015

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Tucson, Arizona, United States +90 more locations

Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy

A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation

Find Trials by Condition in Colorado

Motivational Interviews for Depression in Primary Care

Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus

Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate

A Study of Tasisulam in Treating Participants With Malignant Melanoma

Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting

A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer

Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders

Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older

Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia

A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors

A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer

Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older

Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma

OLIF25™ /OLIF51™ Study

Evaluation of the Accuracy of an Implanted Glucose Sensor

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma